Clarity Pharmaceuticals Ltd. (AU:CU6) has released an update.
Clarity Pharmaceuticals Ltd. has signed an agreement with TerraPower Isotopes for the supply of actinium-225 (Ac-225), essential for its innovative Targeted Alpha-particle Therapy (TAT) program to treat prostate cancer. By securing a stable source of Ac-225 and continuing to work on its copper-67 based treatments, Clarity aims to revolutionize prostate cancer therapy with its dual-targeted bisPSMA products. This strategic move could significantly enhance treatment options and outcomes for cancer patients, positioning Clarity as a pioneer in advanced radiopharmaceuticals for cancer care.
For further insights into AU:CU6 stock, check out TipRanks’ Stock Analysis page.
